Levetiracetam A.Forall

Levetiracetam, the active ingredient in Levetiracetam A.Forall, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy, and is marketed in the European Union.

GNH USA supplies Levetiracetam A.Forall as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable access to this essential antiepileptic medication.

Levetiracetam is an antiepileptic agent used to control seizure activity in various epilepsy syndromes. - Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic-clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: decreases occurrence of rapid muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation or loss of balance. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: depression, suicidal thoughts, or severe anxiety. - Hematologic abnormalities: low blood cell counts such as leukopenia or thrombocytopenia. - Hepatic dysfunction: elevated liver enzymes or jaundice.

When using Levetiracetam, clinicians should consider several precautionary measures to ensure safe therapy. - Renal impairment: adjust dosing in patients with reduced kidney function. - Pregnancy: use only if potential benefit justifies potential risk (Category B). - Concomitant CNS depressants: monitor for additive sedation. - Psychiatric history: observe for emergence or worsening of mood disorders. - Store at ambient temperature: keep vials below 25°C, protect from light and moisture, and retain in original packaging.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring monitoring for toxicity. - Alcohol: additive central nervous system depression, enhancing drowsiness. - Other antiepileptic drugs: combined use may require dose adjustments based on clinical response.